Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: CELLPHIRE, INC.
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2019-12-20 to 2028-07-31
Current total value of award: $53221448
Description: PHASE II CLINICAL TRIAL